| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |